Literature DB >> 10998535

Nociceptin and the micturition reflex.

A Lecci1, S Giuliani, S Meini, C A Maggi.   

Abstract

The i.v. administration of nociceptin (10-100 nmol/kg) inhibits the micturition reflex in a naloxone-resistant manner. The effects induced by i.v. nociceptin were not observed in capsaicin-pretreated animals indicating that i.v. nociceptin inhibits the micturition reflex by inhibiting afferent discharge from capsaicin-sensitive nerves. Supporting this interpretation, nociceptin also inhibited the reflex but not the local bladder contraction induced by topical capsaicin and protects this reflex (but not the local contraction) by desensitization. Intrathecal nociceptin (10 nmol/rat) produces urodynamic modifications similar to those induced by the i.v. administration. Intracerebroventricular (i.c.v.) administration of nociceptin (0.3-1 nmol/rat) also inhibited the micturition reflex in a naloxone-resistant manner suggesting a direct effect on supraspinal sites controlling the micturition. Beyond the inhibitory effects exerted by nociceptin on the micturition reflex, a peripheral excitatory effect mediated by capsaicin-sensitive fibers was also detected. The application of nociceptin (5-50 nmol/rat) onto the bladder serosa when the intravesical volume was subthreshold for the triggering of the micturition reflex, activated the reflex in a dose-dependent manner; the same treatment produced a biphasic effect on the ongoing reflex. In addition to the triggering of micturition reflex, topical nociceptin evokes a local tonic-type contraction that was abolished by the coadministration of tachykinin NK(1) and NK(2) receptor antagonists. Altogether these results indicate that ORL(1) receptors are present at several sites for the integration of the micturition reflex, and that their activation may produce both excitatory or inhibitory effects, depending on the route of administration and the experimental conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998535     DOI: 10.1016/s0196-9781(00)00241-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.

Authors:  Bruno D'Agostino; Giuseppina Marrocco; Marilisa De Nardo; Girolamo Calò; Remo Guerrini; Luca Gallelli; Charles Advenier; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 3.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

4.  New insights into molecular targets for urinary incontinence.

Authors:  Manoj K Poonia; Ginpreet Kaur; Meena Chintamaneni; Ilesh Changela
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

5.  Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation.

Authors:  Marcia R Saban; Ngoc-Bich Nguyen; Timothy G Hammond; Ricardo Saban
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

6.  Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.

Authors:  G Calo; D G Lambert
Journal:  Br J Anaesth       Date:  2018-08-22       Impact factor: 9.166

Review 7.  The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.

Authors:  Lawrence Toll; Andrea Cippitelli; Akihiko Ozawa
Journal:  CNS Drugs       Date:  2021-05-31       Impact factor: 6.497

8.  Overactive bladder syndrome pharmacotherapy: future treatment options.

Authors:  Andrzej Wróbel
Journal:  Prz Menopauzalny       Date:  2015-12-16

9.  A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.

Authors:  Andrzej Wróbel; Aleksandra Szopa; Anna Serefko; Ewa Poleszak
Journal:  Molecules       Date:  2020-03-18       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.